Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2017 16:01 ET | Source: Achaogen Inc.

Achaogen to Participate in the Leerink Partners 6th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
January 05, 2017 08:30 ET | Source: Achaogen Inc.

Achaogen Appoints Halley Gilbert to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
December 19, 2016 16:01 ET | Source: Achaogen Inc.

Achaogen Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
December 14, 2016 09:00 ET | Source: Achaogen Inc.

Achaogen Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
December 12, 2016 16:01 ET | Source: Achaogen Inc.

Achaogen Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
December 12, 2016 07:00 ET | Source: Achaogen Inc.

Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin

-- EPIC registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections (cUTI) -- -- EPIC demonstrates superiority on EMA primary endpoints -- ...
December 11, 2016 19:00 ET | Source: Achaogen Inc.

Achaogen to Host Conference Call and Webcast to Review Plazomicin Phase 3 Clinical Results

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
November 22, 2016 16:02 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
November 15, 2016 16:02 ET | Source: Achaogen Inc.

Achaogen Adds Gary Loeb as General Counsel

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
November 10, 2016 16:01 ET | Source: Achaogen Inc.

Achaogen to Present at the Stifel Healthcare Conference 2016

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...